<p>Assenagon Asset Management S.A. 在第三季度减少了对 Emergent Biosolutions Inc.（纽约证券交易所代码：EBS - 免费报告）的持股比例，降幅为 81.8%，根据该公司最近向证券交易委员会的披露。这家机构投资者在该季度出售了 253,236 股后，持有 56,455 股该生物制药公司的股票。Assenagon Asset Management S.A. 在最近的报告期末持有的 Emergent Biosolutions 的股份约占 0.11%，价值 498,000 美元。</p>
<p>获取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
<ul>
<li>在美联储降息后值得关注的 3 只小盘股</li>
</ul>
<p>其他几家机构投资者和对冲基金也买卖了 EBS 的股票。Vanguard Personalized Indexing Management LLC 在第二季度增加了对 Emergent Biosolutions 的持股，增幅为 14.1%。Vanguard Personalized Indexing Management LLC 目前持有 17,824 股该生物制药公司的股票，价值 114,000 美元，此前在上个季度又购买了 2,204 股。Cetera Investment Advisers 在第二季度将其在 Emergent Biosolutions 的持股增加了 0.7%。Cetera Investment Advisers 目前持有 358,952 股该生物制药公司的股票，价值 2,290,000 美元，此前在上个季度又收购了 2,671 股。EP Wealth Advisors LLC 在第一季度将其在 Emergent Biosolutions 的持股增加了 33.1%。EP Wealth Advisors LLC 目前持有 15,249 股该生物制药公司的股票，价值 74,000 美元，此前在上个季度又收购了 3,790 股。Legal &amp; General Group Plc 在第二季度收购了 Emergent Biosolutions 的新股份，价值约 31,000 美元。最后，Ameritas Investment Partners Inc. 在第二季度购买了 Emergent Biosolutions 的新股份，价值约 35,000 美元。机构投资者持有该公司 78.40% 的股票。</p>
<h2>Emergent Biosolutions 股票表现</h2>
<p>EBS 股票在周五开盘价为 12.63 美元。Emergent Biosolutions Inc. 的一年低点为 4.02 美元，一年高点为 13.41 美元。该公司的市值为 6.6333 亿美元，市盈率为 9.72，贝塔值为 2.32。该公司的债务与股本比率为 1.14，流动比率为 5.76，速动比率为 3.15。该股票的 50 日移动平均价格为 10.94 美元，200 日移动平均价格为 8.86 美元。</p>
<ul>
<li>大幅反弹即将来临？3 只分析师推荐的股票值得密切关注</li>
</ul>
<p>Emergent Biosolutions（纽约证券交易所代码：EBS - 获取免费报告）最近在 1 月 9 日（星期二）发布了季度财报。这家生物制药公司报告的每股收益（EPS）为（1.27 美元）。Emergent Biosolutions 的净利润率为 9.62%，股本回报率为 20.85%。该公司在该季度的收入为 2.225 亿美元。平均而言，股票分析师预测 Emergent Biosolutions Inc. 在当前年度将发布-0.63 的每股收益。</p>
<h2>Emergent Biosolutions 的内部交易</h2>
<p>在相关消息中，董事 Ronald Richard 于 12 月 5 日（星期五）出售了 21,984 股该股票，交易平均价格为 11.97 美元，总交易额为 263,148.48 美元。交易完成后，该董事直接持有 98,417 股公司的股票，估值约为 1,178,051.49 美元。这代表其持股比例减少了 18.26%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，执行副总裁 Coleen Glessner 于 10 月 7 日（星期二）出售了 30,608 股 Emergent Biosolutions 股票，交易平均价格为 10.00 美元，总价值为 306,080.00 美元。交易完成后，该执行副总裁直接持有公司 144,319 股，估值约为 1,443,190 美元。该交易使其持股比例减少了 17.50%。有关此交易的更多细节可在官方 SEC 披露中找到。公司内部人士持有 1.20% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>在市场轮换持续的情况下，关注这 4 只超买股票</li>
</ul>
<p>一些研究分析师最近对该股票发布了报告。Zacks Research 在 10 月 24 日（星期五）的研究报告中将 Emergent Biosolutions 的股票评级上调至 “持有”。HC Wainwright 在 12 月 16 日（星期二）的研究报告中重申了 “买入” 评级，并设定了 15.00 美元的目标价。Weiss Ratings 在周一的研究报告中重新发布了对 Emergent Biosolutions 的 “持有（c-）” 评级。最后，Wall Street Zen 在 11 月 30 日（星期日）的研究报告中将 Emergent Biosolutions 的评级从 “买入” 上调至 “强力买入”。一位研究分析师对该股票给予了买入评级，两位分析师对该股票给予了持有评级。根据 MarketBeat.com，该公司目前的平均评级为 “持有”，平均目标价为 15.00 美元。</p>
<p><strong>查看我们关于 EBS 的最新报告</strong></p>
<h2>关于 Emergent Biosolutions</h2>
<p>（免费报告）</p>
<p>Emergent BioSolutions 是一家全球性的专业生物制药公司，专注于开发、生产和商业化应对公共卫生威胁的医疗对策和专业产品。该公司的产品组合包括疫苗、抗体疗法和旨在保护人们免受生物、化学和新兴传染病威胁的重症护理产品。Emergent 与政府机构（包括美国国防部和生物医学高级研究与发展局（BARDA））建立了长期合作关系，以支持国家应急准备计划。</p>
<p>Emergent 产品线中的关键商业产品包括 BioThrax（炭疽疫苗）、ACAM2000（天花疫苗）和 Vaxchora（霍乱疫苗），以及治疗性产品如 Anthrasil（炭疽免疫球蛋白）和用于阿片类药物过量逆转的纳洛酮鼻喷雾剂 Narcan。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Emergent Biosolutions</li>
<li>在 1 月 1 日前投资 1000 美元于此股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇特的水晶金属性能超越硅达 100 倍</li>
<li>来自奇怪新 “AI 燃料” 的 33000% 繁荣？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于 Emergent Biosolutions 吗？</h2>
<p>在你考虑 Emergent Biosolutions 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Emergent Biosolutions 并不在名单上。</p>
<p>虽然 Emergent Biosolutions 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Assenagon Asset Management S.A. 在第三季度将其在 Emergent Biosolutions Inc. 的持股减少了 81.8%，目前持有 56,455 股，价值 498,000 美元。其他机构投资者，包括先锋集团和 Cetera，也调整了他们在 EBS 的持仓。Emergent Biosolutions 的股票开盘价为 12.63 美元，市值为 6.6333 亿美元。分析师对该股票的评级不一，有些将其升级为 “强力买入”</p>

<p>Assenagon Asset Management S.A. lessened its stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 81.8% in the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 56,455 shares of the biopharmaceutical company's stock after selling 253,236 shares during the quarter. Assenagon Asset Management S.A. owned about 0.11% of Emergent Biosolutions worth $498,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在第三季度减少了对 Emergent Biosolutions Inc.（纽约证券交易所代码：EBS - 免费报告）的持股比例，降幅为 81.8%，根据该公司最近向证券交易委员会的披露。这家机构投资者在该季度出售了 253,236 股后，持有 56,455 股该生物制药公司的股票。Assenagon Asset Management S.A. 在最近的报告期末持有的 Emergent Biosolutions 的股份约占 0.11%，价值 498,000 美元。</p>
</div><p>Get <strong>Emergent Biosolutions</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在美联储降息后值得关注的 3 只小盘股</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also bought and sold shares of EBS. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Emergent Biosolutions by 14.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,824 shares of the biopharmaceutical company's stock worth $114,000 after buying an additional 2,204 shares in the last quarter. Cetera Investment Advisers grew its position in Emergent Biosolutions by 0.7% during the 2nd quarter. Cetera Investment Advisers now owns 358,952 shares of the biopharmaceutical company's stock worth $2,290,000 after acquiring an additional 2,671 shares during the last quarter. EP Wealth Advisors LLC grew its position in Emergent Biosolutions by 33.1% during the 1st quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 3,790 shares during the last quarter. Legal &amp; General Group Plc acquired a new position in Emergent Biosolutions in the 2nd quarter worth about $31,000. Finally, Ameritas Investment Partners Inc. bought a new position in Emergent Biosolutions in the second quarter valued at about $35,000. Institutional investors own 78.40% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也买卖了 EBS 的股票。Vanguard Personalized Indexing Management LLC 在第二季度增加了对 Emergent Biosolutions 的持股，增幅为 14.1%。Vanguard Personalized Indexing Management LLC 目前持有 17,824 股该生物制药公司的股票，价值 114,000 美元，此前在上个季度又购买了 2,204 股。Cetera Investment Advisers 在第二季度将其在 Emergent Biosolutions 的持股增加了 0.7%。Cetera Investment Advisers 目前持有 358,952 股该生物制药公司的股票，价值 2,290,000 美元，此前在上个季度又收购了 2,671 股。EP Wealth Advisors LLC 在第一季度将其在 Emergent Biosolutions 的持股增加了 33.1%。EP Wealth Advisors LLC 目前持有 15,249 股该生物制药公司的股票，价值 74,000 美元，此前在上个季度又收购了 3,790 股。Legal &amp; General Group Plc 在第二季度收购了 Emergent Biosolutions 的新股份，价值约 31,000 美元。最后，Ameritas Investment Partners Inc. 在第二季度购买了 Emergent Biosolutions 的新股份，价值约 35,000 美元。机构投资者持有该公司 78.40% 的股票。</p>
</div><h2>Emergent Biosolutions Stock Performance</h2>
<div class="lb-trans"><h2>Emergent Biosolutions 股票表现</h2>
</div><p>EBS stock opened at $12.63 on Friday. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.41. The company has a market cap of $663.33 million, a P/E ratio of 9.72 and a beta of 2.32. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15. The stock's fifty day moving average price is $10.94 and its 200-day moving average price is $8.86.</p>
<div class="lb-trans"><p>EBS 股票在周五开盘价为 12.63 美元。Emergent Biosolutions Inc. 的一年低点为 4.02 美元，一年高点为 13.41 美元。该公司的市值为 6.6333 亿美元，市盈率为 9.72，贝塔值为 2.32。该公司的债务与股本比率为 1.14，流动比率为 5.76，速动比率为 3.15。该股票的 50 日移动平均价格为 10.94 美元，200 日移动平均价格为 8.86 美元。</p>
</div><ul>
<li>Big Rallies Brewing? 3 Analyst Favorites to Watch Closely</li>
</ul>
<div class="lb-trans"><ul>
<li>大幅反弹即将来临？3 只分析师推荐的股票值得密切关注</li>
</ul>
</div><p>Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The business had revenue of $222.50 million for the quarter. On average, equities analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Emergent Biosolutions（纽约证券交易所代码：EBS - 获取免费报告）最近在 1 月 9 日（星期二）发布了季度财报。这家生物制药公司报告的每股收益（EPS）为（1.27 美元）。Emergent Biosolutions 的净利润率为 9.62%，股本回报率为 20.85%。该公司在该季度的收入为 2.225 亿美元。平均而言，股票分析师预测 Emergent Biosolutions Inc. 在当前年度将发布-0.63 的每股收益。</p>
</div><h2>Insider Transactions at Emergent Biosolutions</h2>
<div class="lb-trans"><h2>Emergent Biosolutions 的内部交易</h2>
</div><p>In related news, Director Ronald Richard sold 21,984 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the completion of the transaction, the director directly owned 98,417 shares of the company's stock, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, EVP Coleen Glessner sold 30,608 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the completion of the sale, the executive vice president directly owned 144,319 shares in the company, valued at approximately $1,443,190. The trade was a 17.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Ronald Richard 于 12 月 5 日（星期五）出售了 21,984 股该股票，交易平均价格为 11.97 美元，总交易额为 263,148.48 美元。交易完成后，该董事直接持有 98,417 股公司的股票，估值约为 1,178,051.49 美元。这代表其持股比例减少了 18.26%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，执行副总裁 Coleen Glessner 于 10 月 7 日（星期二）出售了 30,608 股 Emergent Biosolutions 股票，交易平均价格为 10.00 美元，总价值为 306,080.00 美元。交易完成后，该执行副总裁直接持有公司 144,319 股，估值约为 1,443,190 美元。该交易使其持股比例减少了 17.50%。有关此交易的更多细节可在官方 SEC 披露中找到。公司内部人士持有 1.20% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
</ul>
<div class="lb-trans"><ul>
<li>在市场轮换持续的情况下，关注这 4 只超买股票</li>
</ul>
</div><p>A number of research analysts recently issued reports on the stock. Zacks Research upgraded shares of Emergent Biosolutions to a &#34;hold&#34; rating in a research report on Friday, October 24th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $15.00 price target on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Weiss Ratings reissued a &#34;hold (c-)&#34; rating on shares of Emergent Biosolutions in a research note on Monday. Finally, Wall Street Zen raised Emergent Biosolutions from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday, November 30th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $15.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对该股票发布了报告。Zacks Research 在 10 月 24 日（星期五）的研究报告中将 Emergent Biosolutions 的股票评级上调至 “持有”。HC Wainwright 在 12 月 16 日（星期二）的研究报告中重申了 “买入” 评级，并设定了 15.00 美元的目标价。Weiss Ratings 在周一的研究报告中重新发布了对 Emergent Biosolutions 的 “持有（c-）” 评级。最后，Wall Street Zen 在 11 月 30 日（星期日）的研究报告中将 Emergent Biosolutions 的评级从 “买入” 上调至 “强力买入”。一位研究分析师对该股票给予了买入评级，两位分析师对该股票给予了持有评级。根据 MarketBeat.com，该公司目前的平均评级为 “持有”，平均目标价为 15.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on EBS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 EBS 的最新报告</strong></p>
</div><h2>About Emergent Biosolutions</h2>
<div class="lb-trans"><h2>关于 Emergent Biosolutions</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.</p>
<div class="lb-trans"><p>Emergent BioSolutions 是一家全球性的专业生物制药公司，专注于开发、生产和商业化应对公共卫生威胁的医疗对策和专业产品。该公司的产品组合包括疫苗、抗体疗法和旨在保护人们免受生物、化学和新兴传染病威胁的重症护理产品。Emergent 与政府机构（包括美国国防部和生物医学高级研究与发展局（BARDA））建立了长期合作关系，以支持国家应急准备计划。</p>
</div><p>Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.</p>
<div class="lb-trans"><p>Emergent 产品线中的关键商业产品包括 BioThrax（炭疽疫苗）、ACAM2000（天花疫苗）和 Vaxchora（霍乱疫苗），以及治疗性产品如 Anthrasil（炭疽免疫球蛋白）和用于阿片类药物过量逆转的纳洛酮鼻喷雾剂 Narcan。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Emergent Biosolutions</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Emergent Biosolutions</li>
<li>在 1 月 1 日前投资 1000 美元于此股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇特的水晶金属性能超越硅达 100 倍</li>
<li>来自奇怪新 “AI 燃料” 的 33000% 繁荣？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EBS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Emergent Biosolutions Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于 Emergent Biosolutions 吗？</h2>
</div><p>Before you consider Emergent Biosolutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Emergent Biosolutions 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Emergent Biosolutions 并不在名单上。</p>
</div><p>While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Emergent Biosolutions 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon Asset Management S.A. 在 Emergent Biosolutions Inc. $EBS 中持有价值 49.8 万美元的股票头寸